Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
80
datasets available to search
ShareScore release 0.9.0
Dataset results
80 results for “low-grade glioma”
Return to work following diagnosis of low-grade glioma: A nationwide matched cohort study
<p>Objective: Return-to-work (RTW) following diagnosis of infiltrative low-grade gliomas (LGG) is unknown. </p> <p>Methods: Swedish patients with histopathological verified WHO grade II diffuse glioma diagnosed between 2005-2015 were included. Data were acquired from several Swedish registries. A total of 381 patients aged 18-60 were eligible. A matched control population (n=1900) was acquired. Individual data on sick leave, compensations, comorbidity, and treatments assigned were assessed. Predictors were explored using multivariable logistic regression. </p> <p>Results: One year before surgery/index date, 88 % of cases were working compared to 91 % of controls. The proportion of controls working remained constant, while patients had a rapid increase in sick leave approximately six months prior to surgery. After one and two years respectively, 52 % and 63 % of the patients were working. Predictors for no-RTW after one year were previous sick leave (OR 0.92, 95 % CI 0.88-0.96, p <0.001), older age (OR 0.96, 95 % CI 0.94-0.99, p=0.005) and lower functional level (OR 0.64 95% CI, 0.45-0.91 p=0.01). Patients receiving adjuvant treatment were less likely to RTW within the first year. At two years, biopsy (as opposed to resection), female sex and co-morbidity were also unfavorable, while age and adjuvant treatment were no longer significant. </p> <p>Conclusions: Approximately half of the patients RTW within the first year. Lower functional status, previous sick leave, older age, and adjuvant treatment were risk factors for no-RTW at one year after surgery. Female sex, co-morbidity, and biopsy only were also unfavorable for RTW at two years.</p>
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
ClinicalTrials.gov study NCT01734512. IPD Sharing: NO. Countries: 1. Publications: 1.
Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
ClinicalTrials.gov study NCT00077207. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
ClinicalTrials.gov study NCT02924038. IPD Sharing: NO. Countries: 1. Publications: 1.
Return to work following diagnosis of low-grade glioma: A nationwide matched cohort study
Open the record for dataset details and reuse information.
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
ClinicalTrials.gov study NCT00352495. IPD Sharing: Not stated. Countries: 2. Publications: 1.
FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery
ClinicalTrials.gov study NCT06684795. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
ClinicalTrials.gov study NCT03871257. IPD Sharing: YES. Countries: 3. Publications: 1.
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
ClinicalTrials.gov study NCT04775485. IPD Sharing: Not stated. Countries: 11. Publications: 1.
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
ClinicalTrials.gov study NCT05566795. IPD Sharing: NO. Countries: 30. Publications: 1.
Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas
ClinicalTrials.gov study NCT00276640. IPD Sharing: Not stated. Countries: 12. Publications: 3.
Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA
ClinicalTrials.gov study NCT06610851. IPD Sharing: NO. Countries: 1. Publications: 3.
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
ClinicalTrials.gov study NCT04166409. IPD Sharing: YES. Countries: 3. Publications: 2.
Data from: Post-operative follow-up for selected diffuse low-grade gliomas with WHO grade III/IV foci
Objective: Diffuse low-grade gliomas (DLGG) are defined by a continuous growth and an almost unavoidable malignant transformation. Foci of malignant glioma can be found within DLGG samples obtained from surgical resections. As the medical management of patients is classically based on the higher tumor grade, an immediate adjuvant treatment is usually proposed. To determine whether postponing the medical treatment in selected patients is feasible, we conducted a single-center retrospective study. Methods: Single-center retrospective analysis of a consecutive series of DLGG managed with this conservative strategy. Inclusion criteria were: at least one focus of malignant tumor (grade III-IV, WHO 2016), no previous chemotherapy or radiotherapy, no less than a subtotal resection of the FLAIR tumor volume, no intention of treating with immediate adjuvant therapy, minimum two years of follow-up. The time interval to the following oncological medical treatment was analyzed, as well as the functional and survival results. Results: 45 patients met the inclusion criteria (median age 36.5, median time interval from diagnosis: 7.3 months). Most tumors (86.7%) were IDH-mutant and 1p19q intact (60.0%); 10 presented with grade IV foci. With a median follow-up of 6.3 years, 75.5% of patients received a subsequent medical treatment, after a median time of 3.7 years since surgery. At the time of analysis, 9 patients (20.0%) had died (5-years and 7-years survival rates: 95.2% and 67.0%). Most surviving patients were still active professionally, without seizures. Conclusions: Postponing the medical treatment in DLGG with foci of malignant tumor following total or subtotal resection should be considered in selected patients.
Study of MEK162 for Children With Low-Grade Gliomas
ClinicalTrials.gov study NCT02285439. IPD Sharing: NO. Countries: 1. Publications: 0.
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
ClinicalTrials.gov study NCT04923126. IPD Sharing: YES. Countries: 1. Publications: 0.
Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma
ClinicalTrials.gov study NCT00681473. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
ClinicalTrials.gov study NCT01635283. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma
ClinicalTrials.gov study NCT00003375. IPD Sharing: YES. Countries: 0. Publications: 5.
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
ClinicalTrials.gov study NCT00823459. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.